Skip to Content

Basaglar and Lantus - What is the difference between them?

Answers (1)

Official Answer by Drugs.com 9 Mar 2016

Basaglar is insulin glargine injection, approved in Dec 2015 and manufactured by Eli Lilly. Basaglar is a "follow-on" product to Lantus (insulin glargine injection), made by sanofi-aventis.

They are both long-acting human insulin analogues used for blood glucose (sugar) control in adult and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.

Basaglar is administered subcutaneously once daily by the KwikPen at the same time every day.

The FDA does not consider Basaglar a biosimilar to Lantus. FDA did not approve Basaglar as a biosimilar to Lantus because Lantus was not approved under the Public Health Service Act, so there is no “reference product” for a proposed biosimilar product.

See more with our drug comparison tool:
https://www.drugs.com/compare/basaglar-vs-lantus

Votes: +0
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

How does the drug Lokelma work?

Posted 19 Jun 2018 1 answerFAQ by Drugs.com

How do you take Doptelet?

Posted 19 Jun 2018 1 answerFAQ by Drugs.com

What is the difference between Yonsa and Zytiga?

Posted 19 Jun 2018 1 answerFAQ by Drugs.com

Toujeo vs Lantus - What's the difference between them?

Posted 26 Jun 2018 1 answerFAQ by Drugs.com

Toujeo vs Tresiba - What's the difference between them?

Posted 29 Jun 2018 1 answerFAQ by Drugs.com